Europe's Energy Security Threatened by Cloudy and Windless Days
Bouts of cloudy and windless days — conditions known as 'Dunkelflaute' — are most common in Europe between November and January, typically fueled by high-pressure weather patterns that bring cloudy skies and low wind speeds. Curbed renewables generation during these periods has forced the region to turn to coal or costly gas-fired plants to meet its power needs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
26 minutes ago
- Associated Press
Atalanta signs Poland wing-back Nicola Zalewski after short stay at Inter Milan
BERGAMO, Italy (AP) — Atalanta has signed Nicola Zalewski with the Poland wing-back leaving Inter Milan after just seven months and 17 games, including a Champions League final. Atalanta did not disclose a transfer fee in the deal announced late Monday for the 23-year-old Zalewski. It was reported to be 17 million euros ($20 million). That would be about 10 million euros ($11.7 million) profit for Inter which signed Zalewski on loan from Roma in February. The move was made permanent with a 6.3 million euro ($7.4 million) deal in June, while the club was in the United States at the Club World Cup. Inter lost in the round of 16 against Fluminense. Zalewski will stay in the Champions League this season after Atalanta qualified by placing third in Serie A. In the final last season, he came on as a second-half substitute in Inter's 5-0 loss against Paris Saint-Germain. The Italy-born Zalewski has played 29 times for Poland including two games at the 2022 World Cup in Qatar and two at the 2024 European Championship in Germany Atalanta said Zalewski is its fifth offseason signing for the club, which is majority-owned by United States investor Stephen Pagluica. The team is now coached by Ivan Jurić after the inspirational Gian Piero Gasperini left to join Roma after nine years in Bergamo that brought the 2024 Europa League title. ___ AP soccer:
Wall Street Journal
30 minutes ago
- Wall Street Journal
Mediobanca Gets ECB Approval for Banca Generali Bid
Italy's Mediobanca MB 1.37%increase; green up pointing triangle said it received approval from the European Central Bank to pursue an acquisition of smaller peer Banca Generali BGN 0.79%increase; green up pointing triangle. The ECB's green light comes ahead of a meeting of Mediobanca's shareholders, due to be held Thursday, to vote on the offer and as it seeks to fend off a hostile takeover bid from Banca Monte dei Paschi di Siena BMPS 1.57%increase; green up pointing triangle.
Yahoo
34 minutes ago
- Yahoo
Coloplast A/S - Interim Financial Report, 9M 2024/25
2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin1,2 was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin1 was 27%, on par with last year2. Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. "We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register hereAccess the conference call webcast directly here: Coloplast - 9M 2024/25 conference call For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458Email: dkadim@ Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266Email: dkkhu@ Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981Email: dksdk@ Press and mediaPeter MønsterSr. Media Relations ManagerTel. +45 4911 2623Email: dkpete@ AddressColoplast A/SHoltedam 1DK-3050 HumlebaekDenmarkCompany reg. (CVR) no. 69749917 This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_releaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
